Investor's Business Daily on MSN1d
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Investor's Business Daily on MSN2mon
Merck Dives After Summit — Up 56% — Sneaks In With Keytruda-Walloping PunchMerck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback